Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
Clinical trial NCT03589885 · COMPLETED
Trial details
- NCT number
- NCT03589885
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-19
- Primary completion
- 2019-11-19
- Enrollment
- 122
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.